ACT is presented as a T cell-based therapeutic approach with curative potential in some cancers and active development for ovarian cancer.
First-pass extracted concept
adoptive cell therapy
Candidate: concept label3 source documents8 linked claims
Live refresh every 5sNext refresh in 5s
Aliases
ACT
Extracted Explainers
What the tool is doing
What problem it solves
What it does not solve
Evidence Snippets
Adoptive cell therapy (ACT) has demonstrated curative potential in select cancers, but its translation to solid tumors such as ovarian cancer (OC) has been hindered by multiple factors.
Adoptive cell therapy (ACT), which involves in vitro expansion or genetic engineering of immune cells, is a promising approach to bolster anti-tumor immune responses.
Adoptive cell therapy (ACT) has shown remarkable success in the treatment of some malignancies, particularly leukemia.
Supporting Sources
Linked Claims
Key barriers to ACT efficacy in ovarian cancer include limited T cell persistence, antigen escape, and T cell exhaustion.
Quoted textsource-backed
Key barriers, including limited T cell persistence, antigen escape, and T cell exhaustion, are explored alongside strategies to enhance efficacy.
Translation of adoptive cell therapy to ovarian cancer is hindered by tumor heterogeneity, immune exclusion, and a profoundly immunosuppressive tumor microenvironment.
Quoted textsource-backed
Adoptive cell therapy (ACT) has demonstrated curative potential in select cancers, but its translation to solid tumors such as ovarian cancer (OC) has been hindered by multiple factors, including tumor heterogeneity, immune exclusion, and a profoundly immunosuppressive tumor microenvironment.
Strategies discussed to enhance ACT efficacy include cytokine armoring, checkpoint modulation, metabolic reprogramming, and gene editing.
Quoted textsource-backed
Key barriers ... are explored alongside strategies to enhance efficacy through cytokine armoring, checkpoint modulation, metabolic reprogramming, and gene editing.
The reviewed advances provide a roadmap for overcoming immunologic barriers to ACT in ovarian cancer and for developing more potent, durable, and personalized T cell-based strategies.
Quoted textsource-backed
Collectively, these advances offer a roadmap for overcoming the unique immunologic barriers to ACT in OC and accelerating the development of more potent, durable, and personalized T cell-based strategies.
Adoptive cell therapy has shown remarkable success in some malignancies, particularly leukemia.
Quoted textsource-backed
Adoptive cell therapy (ACT) has shown remarkable success in the treatment of some malignancies, particularly leukemia.
The durability of adoptive cell therapy in solid tumors is limited by dose-limiting toxicities, the immunosuppressive tumor microenvironment, and T-cell exhaustion.
Quoted textsource-backed
However, there are multiple factors that limit the durability of ACT in solid tumors, including dose-limiting toxicities, the immunosuppressive tumor microenvironment, and T-cell exhaustion.
Chimeric antigen receptor T cells, tumor-infiltrating lymphocytes, and T cell receptor-engineered T cells are key adoptive cell therapy modalities in colorectal cancer discussion.
Adoptive cell therapy is a promising approach to bolster anti-tumor immune responses in colorectal cancer.